glp-1 drugs market dynamics 2025 Receptor Agonist Size, Trends and Share Report 2026 Obesity GLP-1 Market

That same study suggested that taking a GLP-1 for 1.5 years or more was associated with a 2.32 times higher chance of a deep vein thrombosis

Finally, a retrospective cohort study compared 1775 matched pairs of SGLT2i users and nonusers with SLE and type 2 diabetes from the TriNetX database and found that use of SGLT2i was associated with significantly reduced risk of lupus nephritis, dialysis, kidney transplant, heart failure, and all-cause mortality compared with no SGLT2i use 8 9,10

Similar content being viewed by others Introduction Diabetes mellitus (DM) affects over 422 million individuals globally, with projections indicating a rise to 783 million by 2045, representing 10.5% of the adult population

Comprehensive, meticulously planned clinical trials that assess the outcomes of GLP-1RA-induced anti-inflammatory properties in various patient groups are essential

WeightWatchers is, however, LegitScript certified and uses only FDA-approved GLP-1s

Clinical studies have demonstrated that patients using semaglutide GLP-1 for weight loss experienced greater reductions in body weight compared to those on placebo